Objective To evaluate the effect of salsalate as an antiinflammatory agent on insulin
resistance and glycemic control in persons with prediabetes. Methods In this double-blind,
placebo-controlled clinical trial, 66 persons who had prediabetes on the basis of the
American Diabetes Association criteria were enrolled. They were randomly assigned to
receive salsalate (3 g daily) or placebo for 12 weeks. Fasting plasma glucose (FPG) and
insulin, glucose 2 hours after oral administration of 75 g of glucose, hemoglobin A 1c, lipid …